These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28583668)

  • 21. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pomalidomide.
    Lacy MQ; McCurdy AR
    Blood; 2013 Oct; 122(14):2305-9. PubMed ID: 23974193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of pomalidomide for the treatment of multiple myeloma.
    Jones JR; Pawlyn C; Davies FE; Morgan GJ
    Expert Opin Drug Saf; 2016; 15(4):535-47. PubMed ID: 26913560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pomalidomide. A last-line treatment option for multiple myeloma.
    Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
    Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
    Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
    Holstein SA; McCarthy PL
    Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 30. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 32. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
    Ríos-Tamayo R; Martín-García A; Alarcón-Payer C; Sánchez-Rodríguez D; de la Guardia AMDVD; García Collado CG; Jiménez Morales A; Jurado Chacón M; Cabeza Barrera J
    Drug Des Devel Ther; 2017; 11():2399-2408. PubMed ID: 28860711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pomalidomide.
    Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
    Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pomalidomide.
    Engelhardt M; Wäsch R; Reinhardt H; Kleber M
    Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
    Sun JJ; Zhang C; Zhou J; Yang HL
    Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
    San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
    Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
    Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
    Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
    Srkalovic G; Hussein M
    Bosn J Basic Med Sci; 2009 Oct; 9 Suppl 1(Suppl 1):S3-S10. PubMed ID: 19912117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
    Barley K; He W; Agarwal S; Jagannath S; Chari A
    Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.